Neumaura Medical, Inc. to Present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021
May 26 2021 - 8:05AM
Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company
focused on developing and commercializing non-invasive wearable
diagnostic devices and supporting personalized lifestyle coaching
programs, today announced that management has been invited to
present at the Summer Solstice - Best Ideas from the Buy Side
Conference, which is being held virtually on June 1 – June 4, 2021.
Chief Executive Officer Faz Chowdhury, Ph.D.
will deliver his corporate presentation on June 2, 2021 at 4:00pm
ET.
The presentation will be webcast live and available for replay
at https://www.webcaster4.com/Webcast/Page/2134/41524
To receive additional information, request an
invitation or to schedule a one-on-one meeting, please email
angie.goertz@issuerdirect.com.
Investors can register here.
About the MicroCap Rodeo Summer Solstice Best Ideas
Conference
The MicroCap Rodeo is back with its third "Best
Ideas Bowl." This conference is a virtual conference that brings
you the top 35 best ideas from the buy side. Qualified
institutional investors recommended each of the 35 companies
represented as one of their best ideas. Those of you who attended
the 2019 MicroCap Rodeo in Austin, Texas, know that we're focused
on alpha.
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology
company developing and commercializing non-invasive wearable
diagnostic devices. The company is currently commercializing
sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb
medical device, is a non-invasive and flexible continuous glucose
monitor (CGM) providing actionable insights derived from real time
glucose measurements and daily glucose trend data, which may help
people with diabetes and pre-diabetes to better manage, reverse,
and prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the U.S. FDA.
proBEAT™ combines non-invasive glucose data processed using
artificial intelligence and a digital healthcare subscription
service and has been launched in the U.S. as a general wellness
product as part of its BEAT®diabetes program.
The Company sits at the intersection of the
global Type 2 diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion pre-diabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com.
Contact:
Jules AbrahamCORE IR917-885-7378julesa@coreir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024